Technology ID
TAB-2149

Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation

E-Numbers
E-055-2009-0
Lead Inventor
McBride, Alison (NIAID)
Co-Inventors
Chapman, Sandra (NIAID)
Vogel, Jonathan (NCI)
Terunuma, Atsushi (NCI)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Oncology
Infectious Disease
Dermatology
Development Status
Early-stage
Lead IC
NIAID
ICs
NIAID
NCI
One of the major limitations of using cultured keratinocytes for research studies is that primary keratinocytes senesce after a few passages. Keratinocytes from specific anatomical sites are also difficult to culture. Scientists at the NIH have demonstrated that primary keratinocytes, from several anatomical sites, when treated with a small-molecule inhibitor of the ROCK protein maintain a proliferative state and become immortal without genetic modification to the cells. Keratinocytes are also the host cells for human papillomaviruses (HPVs) and other viruses and this technology enables the study of those viruses that do not immortalize cells. In addition, this technology may enhance the quantity of material available for skin grafts, as current grafting techniques are limited by the amount of donor material immediately available. Thus, this technology may provide an ideal model environment for producing large quantities of both normal and diseased primary human keratinocytes from small numbers of primary cells from individual hosts or anatomical sites for research purposes, testing of therapeutics, skin graft generation and HPV investigation.
Commercial Applications
  • Promotion of sustained primary human keratinocyte proliferation in vitro.
  • Human skin graft cultures and techniques.
  • Immortalization of both normal and diseased cells from individual hosts.
  • Immortalization of "difficult to establish" keratinocytes from different anatomical sites.
  • In vitro assay for investigating the full life cycle of HPV.
  • In vitro screen for HPV inhibitors.
Competitive Advantages
  • Allows culture and immortalization of many types of keratinocytes that are difficult to establish and pass in culture.
  • Allows isolation of diseased and normal keratinocytes from individual hosts for research and therapeutic purposes.
  • Current HPV investigations are limited by keratinocyte senescence.
  • Skin graft generation is currently dependent on slow culture of limited quantities of donor material.
Licensing Contact:
Hurley, Benjamin
benjamin.hurley@nih.gov